Randomized controlled trials must be simplified to sustain innovation
Cardiovascular outcomes trials are considered a high-risk venture
2015-06-16
(Press-News.org) Randomised controlled trials must be simplified to sustain innovation in cardiovascular diseases, which are still the biggest killer in Europe, according to the Cardiovascular Round Table (CRT).
The CRT is an independent forum established by the European Society of Cardiology (ESC) and comprised of cardiologists and representatives of the pharmaceutical, device and equipment industries. The group's views are published today in European Heart Journal 1*.
Professor Paulus Kirchhof, corresponding author, said: 'Despite marked progress in diagnosis and treatment, cardiovascular diseases are still the biggest killer in Europe and cause substantial morbidity and burden to the health care system. However, drug developers are opting to not develop new cardiovascular medicines, in part due to high perceived risk and development cost.'
The paper published today outlines barriers to investing in cardiovascular research. The authors recommend new ways to conduct clinical research to make investment more attractive and bring drugs to market sooner.
The authors point out that the randomised controlled trial has transformed the practice of medicine and particularly of cardiovascular medicine. However, it has become bloated and inefficient and may be hindering cardiovascular drug development. Several specifics of cardiovascular medicine make investment into cardiovascular drugs less attractive than other fields of medicine, including:
Many cardiovascular therapies require long term treatment to see any effect
Demonstrating incremental risk reduction often requires very large sample sizes
Cardiovascular disease encompasses a diverse range of mechanisms, not all of which are influenced by the agent studied making it difficult to identify patients likely to benefit
Clinical trials are complex and subject to at times contradicting national and regional regulations
Professor Kirchhof said: 'Cardiovascular drug development is partially a victim of its own success, where mortality benefits are the accepted benchmark in the field, and new therapies have traditionally been evaluated in large cohorts. We have developed ever more robust systems to conduct such trials, and are now faced with a total cost that seems prohibitive for some of the novel developments. Progress in prevention of cardiovascular diseases may require more stratified or personalised management approaches in the future.'
It costs up to $12 billion to bring a single drug to market and delays such as long regulatory reviews leave a short window to recoup costs before a patent expires. The authors state: 'The impact of exclusivity loss should not be underestimated; it is increasingly considered a high-risk investment to fund outcome trials in cardiovascular medicine.'
Other obstacles include the high cost when drugs fail in late stage clinical trials. The authors propose solutions to reinvigorate industry investment in cardiovascular research including targeted drug development and evaluation in defined patient populations, and simplifying large randomised trials.
Professor Kirchhof said: 'We propose a streamlined pre-approval evaluation process for new cardiovascular medicines. We envision that a novel agent may initially be tested and approved for a smaller target population, underpinning the emerging concept of personalised cardiovascular medicine, and that further safety and efficacy data can be collected after the initial (conditional) approval. This will mitigate the risk for drug developers, and provide earlier access to novel therapies for patients.'
He added: 'Another, parallel approach would be to reduce the resource use in controlled trials, and to make use of modern IT based health and social records to collect information on death and severe cardiovascular outcomes, for example.'
Professor Kirchhof concluded: 'Novel approaches are urgently needed for developing new cardiovascular therapies to reduce the unacceptably high burden of disease. Regulators have an important role in making sure that only safe therapies are used in patients. This paper was developed with active involvement of the European Medicines Agency (EMA), which has recognised the problem we are trying to address. The ESC is confident that the EMA will be open to testing some of the novel solutions we propose.'
INFORMATION:
References
1*Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal. 2015; doi:10.1093/eurheartj/ehv2013
2Championing cardiovascular health innovation in Europe. European Heart Journal. 2013;34(33):2630-2635. doi: 10.1093/eurheartj/eht211.
Notes to Editors:
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About the European Heart Journal
The European Heart Journal is the flagship journal of the European Society of Cardiology (http://www.escardio.org). It is published on behalf of the ESC by Oxford Journals, a division of Oxford University Press.
A meeting on 'Improving Clinical Trials' will take place in London, UK, on 9 October 2015 hosted by the CRT where this topic will be discussed further with key stakeholders including regulators, policy makers, industry, academia, patients, statisticians and medical societies.
A PDF of the full paper is available upon request to the ESC Press Office.
ELSE PRESS RELEASES FROM THIS DATE:
2015-06-16
New guidelines providing information, guidance and recommendations for people working with those with hoarding difficulties are launched today, Tuesday 16 June 2015, in London by the British Psychological Society's (BPS) Division of Clinical Psychology (DCP).
The free guidelines, 'A psychological perspective on hoarding: DCP good practice guidelines' have been compiled by clinical psychologists, using expertise and evidence from this area of research. It also includes contributions from those living with hoarding issues as well as their carers.
Lead Consultant Clinical ...
2015-06-16
An innovative programme of activities used in Ugandan primary schools has succeeded in reducing violence by teachers against children by 42%, according to new research published in The Lancet Global Health. The study is published on 16 June, the Day of the African Child.
The Good School Toolkit is a behavioural intervention designed by Ugandan NGO Raising Voices, which aims to foster change in operational culture at the school level. Its materials include t-shirts, books, booklets, posters and guides for around 60 different activities. [1] To evaluate the Toolkit's effectiveness, ...
2015-06-16
Eating up to 100 g of chocolate every day is linked to lowered heart disease and stroke risk, finds research published online in the journal Heart.
There doesn't seem to be any evidence for cutting out chocolate to lower the risk of cardiovascular disease, conclude the researchers.
They base their findings on almost 21,000 adults taking part in the EPIC-Norfolk study, which is tracking the impact of diet on the long term health of 25,000 men and women in Norfolk, England, using food frequency and lifestyle questionnaires.
The researchers also carried out a systematic ...
2015-06-16
The UK hospital post mortem is on the verge of extinction, having already disappeared completely in around a quarter of NHS trusts, reveals a survey published online in the Journal of Clinical Pathology.
Post mortems are carried out in only just over half of one per cent of all UK hospital deaths, the responses show.
The practice of post mortem examination or autopsy dates back to mummification and human dissection in 3000 BC, but is thought to have entered medical practice in its current form in the 1800s.
The researchers base their findings on Freedom of Information ...
2015-06-15
PITTSBURGH, June 15, 2015 - Gene therapy to reduce production of a brain protein successfully prevented development of Parkinson's disease in an animal study, according to researchers at the University of Pittsburgh School of Medicine. The findings, published online today in the Journal of Clinical Investigation, could lead to new understanding of how genetic and environmental factors converge to cause the disease, and the development of effective treatments to prevent disease progression.
Scientists have observed dysfunction of mitochondria, which make energy for cells, ...
2015-06-15
MAYWOOD, IL - About 20 percent of Americans spend time in an intensive care unit around the time of their death, and most deaths follow a decision to limit life-sustaining therapies.
Physicians have a responsibility to provide recommendations to families of dying patients, a Loyola University Medical Center critical care physician writes in the journal Chest.
"A physician has a responsibility to present surrogates with the plan of care he or she believes to be in the best application of a patient's authentic values and interests to a specific clinical situation," Paul ...
2015-06-15
Higher supermarket prices for eco-friendly palm oil could help save endangered species - according to University of East Anglia (UEA) research.
Palm oil is used by the food industry as a cheap substitute for butter. But the conversion of tropical forests to oil palm plantations has had a devastating impact on a huge number of plant and animal species including tigers, elephants, rhinos and orang-utans.
New research published today reveals that a willingness among consumers to pay more for sustainably-grown palm oil would incentivise producers to engage with conservation ...
2015-06-15
Consumers will pay higher prices for palm oil made by companies that help to protect endangered species, finds a new study by North American and U.K. researchers.
Palm oil is widely used in processed food and cosmetics. But the conversion of tropical forests to oil palm plantations has devastated a huge number of plant and animal species, including tigers, elephants, rhinos and orangutans.
The study, published today in the Proceedings of the National Academy of Sciences, finds that shoppers' willingness to pay more for sustainably grown palm oil could create profitable ...
2015-06-15
Researchers at the Stanford University School of Medicine have determined that toothed whales lack functional Mx genes -- a surprising discovery, since all 56 other sequenced mammals in the study possess these genes to fight off viruses like HIV, measles and flu.
Modern toothed whales, including dolphins, orcas and sperm whales, have inherited defunct copies of the Mx1 and Mx2 genes, profoundly altering their immune systems. The basic role of these Mx genes is to make proteins that fight viral infections. The researchers hope that understanding this newly discovered mysterious ...
2015-06-15
DURHAM, N.C. -- Measures taken to protect ecosystems and the environment could also deliver public health benefits, according to a study published today.
While research has shown that nearly one quarter of the global burden of disease can be attributed to poor environmental quality, very little scientific evidence supports the claim that the conservation of ecosystems benefits human health.
To address this knowledge gap, Subhrendu Pattanayak, a Duke professor of global health, environment and public policy, and his colleagues analyzed an extensive set of data consisting ...
LAST 30 PRESS RELEASES:
[Press-News.org] Randomized controlled trials must be simplified to sustain innovation
Cardiovascular outcomes trials are considered a high-risk venture
